Population
Patients who received inpatient chemotherapy from April 2010 through May 2013
Design
Cohort
Follow-up
30 days after discharge
Key result
The baseline 30-day chemotherapy-related readmission rate was 11.1%, with risk factors including age ≥65, hematologic cancer, first cycle chemotherapy, Medicare, SNF discharge, and anthracyclines.
Authors
Loading...
May inform readmission risk stratification in oncology; hypothesis-generating pending prospective validation.
Observational
Identified key risk factors for 30-day chemotherapy-related readmissions, highlighting modifiable factors such as discharge to a skilled nursing facility and anthracycline administration.
Lund et al. (2015) conducted an observational in Inpatient chemotherapy. Risk factors (age ≥65, hematologic cancer, first cycle chemotherapy, Medicare, SNF discharge, anthracyclines) was evaluated on 30-day chemotherapy-related readmission (CRR). The baseline 30-day chemotherapy-related readmission rate was 11.1%, with risk factors including age ≥65, hematologic cancer, first cycle chemotherapy, Medicare, SNF discharge, and anthracyclines.